Skip to main content
. 2019 Feb 16;110(3):1012–1020. doi: 10.1111/cas.13932

Figure 2.

Figure 2

Best response change from baseline in tumor size for each patient as assessed per RECIST version 1.1 per central review. ALK, anaplastic lymphoma kinase translocation; EGFRm, epidermal growth factor receptor mutant; PD‐L1, programmed death ligand 1; RECIST, Response Evaluation Criteria in Solid Tumors; TPS, tumor proportion score